Introduction
============

Invasive micropapillary carcinoma (IMPC) is an aggressive histological subtype of invasive cancer of the breast [@B1], [@B2]. Firstly described by Fisher in 1980 [@B3], pure IMPC is characterized by tumor cells arranged in typical nets papillary surrounded by an obliterated lumina [@B4], [@B5]. The formal concept of IMPC was initially put forward by Siriaunkgul et al in 1993 [@B6]. Given its unique morphological characteristics and greater invasiveness, IMPC was listed as an independent subtype in the 2003 World Health Organization classification of breast cancer [@B7]. Although it is widely accepted that IMPC has a more aggressive behavior, it remains unclear whether this behavior translates into poor prognosis [@B8], [@B9]. What\'s more, given its dissimilarity to the common histology of breast cancer, the rareness of IMPC should be emphasized in clinical practice [@B10].

Previous studies on IMPC often had bias caused by a small patient cohort and the limited follow-up time due to tumor rarity. The strategies in the clinical guidelines for the treatment of IMPC are based on those for the treatment of invasive ductal carcinoma (IDC). Therefore, a specific prognosis evaluation system for IMPC should be utilized to guide treatment strategies in clinical practice [@B1], [@B11]. On other hand, the causes of death other than cancer are competing risks among patients with early breast cancer. Thus the cause-specific endpoints were always chosen as endpoint for these studies. However, the Kaplan-Meier method and the Cox proportional hazards model fail to estimate cancer specific death [@B12].

More recently, nomogram as a prognostic and predictive model have been proposed as reliable and alternative tools to integrate pathological, molecular and clinical characteristics of a disease and consequently establish an evaluation system for the prediction of individual patient outcomes [@B13]. We attempted to construct a nomogram for IMPC and IDC based on nationwide, population-based clinicopathological and molecular data from Surveillance, Epidemiology, and End Results (SEER) database.

Patients and methods
====================

Inclusion and exclusion criteria
--------------------------------

The SEER database includes information on cancer samples from 18 population-based cancer registries and is updated annually to reflect the latest real-world information about cancer. The SEER. Stat software was used to identify patients with breast cancer from January 2001 to December 2015. The specific inclusion criteria were identified as follows: (1) histology ICD-O-3 was limited to IDC (8500/3), IMPC (8507/3), (2) patients without distance metastasis at diagnosis, and (3) the age at diagnosis was between 20 and 80. The exclusion criteria were as follows: (1) the detailed information lacks race, marital status or age, (2) patients with multiple primary tumors, (3) survival time less than 1 month, (4) unknown cause of death, (5) patients with metastatic disease, (6) T classification: unknown, and (7) N classification: unknown.

We randomly divided the entire cohort into a train cohort (75%) and validation cohort (25%) for development and validation of the competing risks nomogram.

The gene expression profiles of GSE66418 were downloaded from the Gene Expression Omnibus (GEO) database, which contains 124 samples, including 73 IMPC samples and 51 matched invasive carcinomas of no special type samples (ICNST). GSE66418 was based on the GPL6801platform \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array, and submitted by Gruel et al [@B14].

Variable declaration
--------------------

Race was divided into white, black and others. The age was regrouped as 20-50yrs (young) and 51-80yrs (old). Marital status was listed as married, single and divorced. The hormone receptor (HR) status of the tumor was stratified as HR-positive and HR-negative. The chemotherapy variable was classified only as chemotherapy "yes" or "no/unknown".

Statistical analysis
--------------------

Propensity score matching (PSM) is a statistical method that reduces confounding from measured variables in observational data. In regression adjustment for the propensity score, a treatment case is matched with one or more control cases based on their propensity scores [@B15]. Patients with the same propensity score have the same distribution of measured confounders. Provided that there is no unmeasured confounding, we obtain unbiased estimates of the treatment effect by comparing treatment groups within levels of the propensity score [@B16].

Patients with early stage low-risk breast cancer detected by mammography screening programs, are expected to survive breast cancer are at a higher risk of non-BCSD [@B17]. To obtain unbiased estimates of the risk of BCSD, we applied a proportional subdistribution hazards regression (competing risk model), which connects the regression coefficients to a cumulative incidence function to estimate the unbiased risks in the presence of competing risks [@B18].

Categorical variables were compared using the Chi-Squared test. BCSD was calculated from the date of breast cancer diagnosis to the date of death due to breast cancer. Death due to other causes was defined as competing risks. Overall mortality was analyzed using the Kaplan-Meier method between groups with a log-rank test for significance. A proportional subdistribution hazards regression (competing risk model) was used to determine factors associated with BCSD. Prognostic factors with a *P* value \< 0.05 in univariate analysis were incorporated into multivariate analysis. A *P* value \< 0.05 was considered to be statistically significant in the multivariate analysis, while subdistribution hazard ratio (SHR) and a 95% confidence interval (CI) were used to adjust for prognostic variables. BCSD was set as the primary endpoint, because one of the primary goals of therapy is to reduce death attributable to the underlying breast cancer. In addition, Overall mortality was set as the secondary endpoint. To avoid multicollinearity, the multivariable analysis included the variables of T-classification, N-classification, ER (Estrogen receptor) status and PR(Progesterone receptor) status rather than the variables of stage and HR status.

A nomogram was established based on the competing risk regression model to predict the individual outcomes of BCSD at 3 years, 5 years, and 10 years. Age at diagnosis, race, marital status, tumor location, differentiation grade, histology, T classification, N classification, and ER and PR status were included in the model. The prognostic accuracy of the nomogram model was validated by internal validation, with bootstrapping to calculate a relatively unbiased measure of the ability to discriminate between patients as measured by the concordance index (C-index). The calibration was evaluated by plotting the observed Gray 3-year proportions, 5-year proportions and 10-year proportions compared with the corresponding nomogram for the 3-year, 5-year or 10-year predicted BCSD. Likewise, an external validation was performed in the validation cohort. The C-index was also used to quantify the discrimination ability of the prediction model. Since this study utilized data from the SEER database, which contained no personal identifying information, ethical approval and informed consent from patients in current study were not required.

All analysis was performed using the statistical software and R software (version 3.5.0). Rms package was used to performance survival analysis. Limma package was used to identify differentially expressed genes (DEGs) between IMPC and ICNT groups[@B19]. The adjusted *P* values \< 0.05 and absolute fold change (FC) ≥ 2.0 were considered as the cutoff values. ClusterProfiler package was used to analyze the functions of DEGs [@B20]. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed.

Result
======

Clinicopathological characteristics
-----------------------------------

A total of 332033 patients with early breast cancer were included in the study. The median age of the 330786 (99.62%) patients with IDC was 57 years compared with 58 years in the 1247 (0.38%) patients with IMPC. IMPC patients with larger tumor size (T3) (8.74% vs 4.54%; *P* \< 0.001), more lymph node involvement (51.48% vs 33.73%, *P* \< 0.001), and a higher stage (stage II 38.97% vs 37.88%, stage III 23.5% vs 12.45%, *P* \< 0.001) compared with those with IDC. And IMPC was also related to a higher frequency of ER-positive and PR-positive status (88.69% vs 77.52%, *P* \< 0.001; 78.75% vs 67.51%, *P* \< 0.001, respectively) as well as an obviously higher frequency of HR-positive status (89.17% vs 78.87%, *P* \< 0.001) compared with IDC. Additionally, similar percentages of patients with either IMPC or IDC were receiving. Compared to IDC group, IMPC group has a significant higher rate of receiving radiation treatment (59.42% vs 56.36%, *P* = 0.029) and chemotherapy treatment ((55.73% vs 48.92%, *P* \< 0.001). IMPC group had a significant lower rate of breast conserving surgery (56.05% vs. 61.18%, *P* \< 0.001). 35.12% of patients had at least 10 lymph nodes removed in IMPC group, which was significant higher than 29.48% in IDC group (*P* \< 0.001). Given the clear group differences between IDC and IMPC group, propensity scores describing the likelihood of histology contingent on covariates were used to reweight the patient population for each group. Many distributional differences were eliminated, yielding IDC and IMPC group that were more similar (**[Supplementary Figure 1](#SM0){ref-type="supplementary-material"}**). The characteristics of the patients were shown in **Table [1](#T1){ref-type="table"}**.

Survival analysis based on the Kaplan-Meier and Gray method
-----------------------------------------------------------

The median follow-up time for patients in the study was 64 months (range 1-179 months). After a PSM adjustment, based on Kaplan-Meier analysis, patients with IMPC had a favorable prognosis with marginal statistical significance compared with patients with IDC (overall mortality HR = 0.68; 95%CI, 0.53-0.86; *P* = 0.002). The cumulative incidence of the 3-year, 5-year and 10-year overall mortality for IMPC were 4.17%, 7.74% and 17.89%, respectively, compared with 6.73%, 13.15% and 26.08% respectively, in patients with IDC (**Fig. [1](#F1){ref-type="fig"}**). Based on Gray method, patients with IMPC had a favorable prognosis with significant statistical significance compared with patients with IDC (BCSD SHR = 0.64; 95%CI, 0.47-0.88; *P* = 0.006). The 3-year, 5-year and 10-year BCSD for the IMPC group was 3.58%, 4.84% and 10.94% compared with 4.05%, 8.93% and 16.24% for the IDC group.

Furthermore, we stratified the entire cohort by histology and analyzed BCSD according to patient and tumor characteristics based on univariate analysis of the competing risk regression model. The forest plot of subgroup analysis revealed that, in the young, white, married, left, other location, moderate-well, T2, N2, N3, stage III, ER positive, PR positive, HR positive, number of lymph node resected (nLN) \> 10, with radiotherapy, with chemotherapy, with breast conserving and mastectomy surgery subgroups, patients with IMPC had a favorable prognosis compared with patients with IDC. In the divorce subgroup, patients with IDC had a favorable prognosis. Except for listed above subgroups, there was no significant difference between IMPC and IDC subgroup (**Fig. [2](#F2){ref-type="fig"}**).

Prognostic factors for IMPC and IDC based on competing risk model
-----------------------------------------------------------------

We randomly divided the entire cohort into two parts: a train cohort (249024 patients) and a validation cohort (83009 patients). Relevant baseline variables were similarly distributed in the development and validation cohorts (**Table [2](#T2){ref-type="table"}**). The competing risk regression model was used to explore the prognostic factors for patients with IMPC and IDC. Univariate analysis showed the race, marital status, differentiated grade, histology, T-classification, N-classification, stage and ER status, PR status, HR status, nLN, surgery, and chemotherapy were statistically significant prognostic factors for survival. Prognostic factors with a *P* value \< 0.05 according to univariate analysis were incorporated into the multivariate analysis. Multivariate analysis showed the race, grade, histology, T-classification, N-classification, HR status, and nLN were statistically significant prognostic factors for BCSD (**Table [3](#T3){ref-type="table"}**).

Construction of a nomogram model
--------------------------------

A nomogram was constructed based on statistically significant factors identified by multivariate analysis from the competing regression model to predict the risk of BCSD in resectable breast cancer. The factors consisted of the race, grade, histology, T-classification, N-classification, HR status, and nLN. N-classification was the most predominant prognostic factor, followed by T-classification, nLN, race, HR status, grade and histology (**Fig. [3](#F3){ref-type="fig"}**). A vertical line was drawn from the factor to the point scale to determine the score of all variables (detailed in **Table. [4](#T4){ref-type="table"}**). We then summarized all of the discrete values and drew a straight line from the total scale to the 3-year, 5-year, and the 10-year BCSD estimated lines to obtain the 3-year, 5-year, and 10-year BCSD rate. The bootstrap method was used to perform the internal validation. The C-index for the nomogram was 0.835 (95%CI: 0.830-0.843). The calibration plots showed a strong agreement for the 3-year, 5-year and 10-year BCSD rate between the nomogram prediction and realistic observation. In the external validation, the C-index for the nomogram was 0.818 (95%CI: 0.813 -0.821). The calibration plots showed a strong agreement for the 3-year, 5-year and 10-year BCSD rate between the nomogram prediction and realistic observation (**Fig. [4](#F4){ref-type="fig"}**).

Identification of key genes and pathways in IMPC using bioinformatics analysis
------------------------------------------------------------------------------

To better understand whether IMPC is a unique biological disease, DEGs were identified between IMPC samples and ICNST samples. In present study, a total of 53 upregulated DEGs and 40 downregulated DEGs of IMPC was identified (**Supplementary** Table [3](#T3){ref-type="table"}). Heatmap of the differentially expressed genes between IMPC samples and ICNST samples, with red indicating higher expression and green indicating lower expression (**[Supplementary Fig. 2](#SM0){ref-type="supplementary-material"}**). The GO analysis results showed that downregulated DEGs were significantly enriched in the following biological processes: extracellular structure organization, serine-type peptidase activity, extracellular matrix, cell-substrate adherens junction, cell-substrate junction. KEGG analysis of selective gene sets shows that upregulated DEGs significantly enriched for processes related to signal pathways: regulation of lipolysis in adipocytes, while downregulated DEGs significantly enriched for processes related to carbon metabolism, Rap1 signaling pathway.

Discussion
==========

IMPC is a distinct histological subtype of breast cancer with a highly aggressive nature upon initial presentation [@B21]-[@B23]. In the current study, IMPC comprised 0.30% of the entire cohort, while previous studies found that IMPC accounted for \< 3.0% of all breast cancers [@B9], [@B24]. Previous studies have indicated that IMPC usually presents with a later stage and has a higher propensity for lymph node involvement [@B11], [@B25]-[@B27]. Consistent with previous studies, our study demonstrated that patients with IMPC had more T3 tumors, a higher rate of N1-N3 nodal metastases, and a higher frequency of ER-positive, PR-positive, and HR-positive status. Previous studies showed that tumors containing the IMPC component tended to present with a larger size. Across clinical presentations, radiographic findings, locations and gross features, there were no obvious differences between IMPC and IDC [@B28]. It remains controversial whether the percentage of the micropapillary component is significant for either lymph node invasion or survival outcomes [@B1], [@B29]. The criteria for distinguishing between mixed and pure IMPC remain imprecise [@B28]. Molecular-genetic studies found that pure and mixed IMPC were remarkably similar at the genetic level [@B24]. Therefore, the presence of the IMPC component, rather than its percentage should be emphasized. The prognostic significance of tumor size in IMPC patients still requires further validation.

In the current study, IMPC had similar lymph node involvement (52.48%) compared with the range (40.3%-84.8%) of previous studies on IMPC which was significantly higher than that of IDC [@B8]. Ide et al suggested that 8.4% of breast cancer lesions contained the IMPC component in their study of 486 patients. They showed that the presence of the IMPC component alone was a significant predictive factor for lymph node metastasis, even if it was detected in only a small proportion of the tumor [@B1]. Simonetti\'s study demonstrated that IMPC had high expression of CD24 and low expression of CD44 compared with IDCs, which might explain the increased propensity for lymph node metastasis [@B30].

The prognosis of IMPC compared with IDC remains a topic of debate. Chen et al analyzed 100 patients with IMPC with a median 5-year follow-up and revealed that IMPC had a worse OS outcome than IDC (59% vs 77%, *P* = 0.004). This was consistent with a retrospective multicenter study by Shi (OS, 75.9% vs 89.5%;*P*\<0.001). However, more recently, several studies referring to the outcomes of OS suggested that the OS of IMPC was not inferior to that of IDC [@B8], [@B10], [@B11], [@B31], [@B32]. Liu et al reported that patients with IMPC had similar prognosis compared with lymph node matched IDC patients, patients with IDC had a favorable prognosis in the T1N2-3 subset, whereas IMPC patients demonstrated comparatively better prognosis in the T2N2-3 subgroup [@B29]. The relationship between IMPC and prognosis may be confused by other factors in the univariate analysis. The prognostic value of IMPC was demonstrated via multivariate analysis (*P* \< 0.001). After the adjustment for prognostic factors, especially the T- and N-classification, histology was significantly associated with BCSD (SHR = 0.64; 95%CI, 0.47-0.88; *P* = 0.006). IMPC correlates with an advanced stage (higher T- and N-classification), which is related to an unfavorable survival outcome, and may mask the prognostic value of IMPC for OS in univariate analysis. The established nomogram based on the competing regression model demonstrated that IMPC had favorable clinical outcomes compared with those of IDC, and that prognostic value of IMPC exceeded prognostic factors, grade. Therefore, IMPC might be an independent favorable prognostic factor for patients with breast cancer.

Lymph node metastasis and larger tumor size are widely considered unfavorable prognostic factors in the clinical practice. However, inferior clinical characteristics did not translate into a poor prognosis in the IMPC cohort. Lymph node status, primary tumor size, and clinical characteristics will often determine the follow-up treatment, including chemotherapy, radiation, and endocrine therapy [@B5]. Given the inferior clinicopathologic characteristics, clinicians usually chose aggressive treatment in clinical practice. Patients with IMPC have a higher probability of receiving endocrine therapy compared with patients with IDC due to higher HR positivity. In the study by Tang et al, a total of 898 patients (170 IMPC and 728 IDC) were enrolled. Hormone therapy was administered to 607 patients with HR positivity, of whom 135 (79.41%) were IMPC patients and 472 (64.84%) were IDC patients (*P* \< 0.001) [@B33]. Previous studies identified that IMPC patients had higher histological grades than IDC patients (*P* \< 0.05) [@B31], [@B33], [@B34]. Liu et al observed a significantly higher percentage (92.2%, *P* = 0.044) of IMPC patients receiving a regimen containing anthracycline compared with IDC patients (79.4%) [@B35]. A previous study identified that compared with IDC Patients, IMPC patients received chemotherapy more frequently, although the difference was not statistically significant [@B31], [@B33]. In addition, patients with IMPC were more likely to undergo resection with axillary lymph node dissection [@B36]. In our study, 38.45% of patients had at least 10 lymph nodes removed in IMPC group, which was significant higher than 30.55% in IDC group (*P* \< 0.001).

IMPC as a unique entity is characterized by proliferation of carcinomatous cells organized in nesting pattern, separated from the extracellular matrix by an artifactually created spaces with the cellular apical surface polarity towards the outside[@B22], [@B37]. Determining whether a specific gene profile may cause abnormalities in IMPC polarity, the present study identified DEGs and signal pathways in IMPC. The GO functions reveal that cell-substrate interactions are among top affected molecular functions in downregulated DEGs for IMPC. This may suggests an important role for downregulated DEGs in promoting cellular polarity and shape maintenance [@B14], [@B37]. In cell adhesion, cell-cell interactions between cancer cells with endothelium determine the metastatic spread [@B38]. This may explain why IMPC has a higher rate of lymph node metastasis. Unfortunately, the gene expression profiles we used do not provide additional clinical information. Our genomic analyses have not identified direct specific genomic aberration that may explain clinical behavior of IMPC.

To the best of our knowledge, this is the first individual estimated nomogram for IMPC based on a multicentric large-population cohort. The value of the constructed nomogram is its ability to help guide treatment decision making with high cost-efficacy since specific guidelines have not been generated for this rare histological type. The C-index for the nomogram was 0.835 (95%CI: 0.830-0.843), which indicated accurate prognostic prediction for individual survival outcomes. Further studies should focus on how the widely-accepted inferior characteristics of IMPC that did not translate into a worse prognosis could be attributed to more intensive hormone therapy, more frequent chemotherapy, and distinct features, including a higher histological grade or the molecular and genetic mechanisms that underlie the highly aggressive nature of IMPC.

Limitation
==========

Retrospective analyze are often affected by various biases. Information about is absent in the SEER database, which is important to this study. Thus, there was no clearly defined relationship between the established nomogram and chemotherapy. SEER database also lacks records of molecular information, such as HER2 status and Ki67, such information is also important to establish an intrinsic subtype model.

Conclusion
==========

In conclusion, our present study focused on IMPC, a rare type of breast cancer that accounted for 0.3% of the entire cohort. IMPC was found to be a favorable independent prognostic factor. The present study identified gene expression profiles and signal pathways of IMPC, which deepen our understanding of the molecular mechanisms of IMPC. The nomogram generated in this study is the first to predict the survival outcomes for IMPC, it accurately predicts early breast cancer outcomes, and provides a reference for informed decision making in clinical practice.
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![**The survival of patients with IMPC and IDC based on Kaplan-Meier and Gray analysis**. IMPC: Invasive micropapillary carcinoma; IDC: Infiltrative ductal cancer; BCSD: Breast cancer specific death.](jcav10p6801g001){#F1}

![**Forest plot of subgroup analysis.** IMPC: Invasive micropapillary carcinoma; IDC: Infiltrative ductal cancer; SHR: Subdistribution hazard ratio; CI: Confidence index.](jcav10p6801g002){#F2}

![**Nomogram to predict the probability of BCSD.** The factors of marital status, differentiated grade, histology, T-classification, N-classification, HR status, and nLN were included in the model. IMPC: Invasive micropapillary carcinoma; IDC: Infiltrative ductal cancer; BCSD: Breast cancer specific death.](jcav10p6801g003){#F3}

![**Internal and external validation of the nomogram.** Calibration curves, which plot the average Gray estimate against the corresponding nomogram for 3-, 5- or 10- year predicted BCSD, were provided to evaluate the performance of the nomogram. The plot presented excellent agreement between the nomogram prediction and the actual observation for 3-, 5 and 10- year CSS. BCSD: Breast cancer specific death.](jcav10p6801g004){#F4}
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The characteristics of patients with resectable breast cancer

                          Before PSM\*     After PSM\*                                             
  ----------------------- ---------------- -------------- ---------- -------------- -------------- -------
  Age                                                     \< 0.001                                 0.779
  Young                   188118(56.87%)   638(51.16%)               631(50.6%)     638(51.16%)    
  Old                     142668(43.13%)   609(48.84%)               616(49.4%)     609(48.84%)    
  Race                                                    0.018                                    0.802
  White                   262840(79.46%)   951(76.26%)               965(77.39%)    951(76.26%)    
  Black                   36159(10.93%)    162(12.99%)               154(12.35%)    162(12.99%)    
  Other                   31787(9.61%)     134(10.75%)               128(10.26%)    134(10.75%)    
  Marital status                                          0.079                                    0.847
  Married                 205695(62.18%)   746(59.82%)               759(60.87%)    746(59.82%)    
  Single                  50051(15.13%)    216(17.32%)               207(16.6%)     216(17.32%)    
  Divorce                 75040(22.69%)    285(22.85%)               281(22.53%)    285(22.85%)    
  Laterality                                              0.887                                    0.841
  Left                    167545(50.65%)   627(50.28%)               622(49.88%)    627(50.28%)    
  Right                   163196(49.34%)   620(49.72%)               625(50.12%)    620(49.72%)    
  Unknown                 45(0.01%)        0(0%)                     0(0%)          0(0%)          
  Location                                                0.001                                    0.946
  Central portion         15190(4.59%)     64(5.13%)                 57(4.57%)      64(5.13%)      
  Upper-inner quadrant    41080(12.42%)    176(14.11%)               182(14.6%)     176(14.11%)    
  Lower-inner quadrant    19594(5.92%)     84(6.74%)                 78(6.26%)      84(6.74%)      
  Upper-outer quadrant    119222(36.04%)   372(29.83%)               377(30.23%)    372(29.83%)    
  Lower-outer quadrant    24612(7.44%)     105(8.42%)                97(7.78%)      105(8.42%)     
  Other                   111088(33.58%)   446(35.77%)               456(36.57%)    446(35.77%)    
  Differentiation grade                                   0.039                                    0.772
  Moderate-well           132839(40.16%)   465(37.29%)               472(37.85%)    465(37.29%)    
  Undifferentiated-Poor   197947(59.84%)   782(62.71%)               775(62.15%)    782(62.71%)    
  T-classification\*                                      \< 0.001                                 0.766
  T1                      207581(62.75%)   712(57.1%)                718(57.58%)    712(57.1%)     
  T2                      100128(30.27%)   388(31.11%)               398(31.92%)    388(31.11%)    
  T3                      15019(4.54%)     109(8.74%)                99(7.94%)      109(8.74%)     
  T4                      8058(2.44%)      38(3.05%)                 32(2.57%)      38(3.05%)      
  N-classification \*                                     \< 0.001                                 0.990
  N0                      219196(66.27%)   605(48.52%)               607(48.68%)    605(48.52%)    
  N1                      80924(24.46%)    399(32%)                  398(31.92%)    399(32%)       
  N2                      20198(6.11%)     134(10.75%)               137(10.99%)    134(10.75%)    
  N3                      10468(3.16%)     109(8.74%)                105(8.42%)     109(8.74%)     
  Stage \*                                                \< 0.001                                 0.828
  I                       164286(49.67%)   468(37.53%)               469(37.61%)    468(37.53%)    
  II                      125302(37.88%)   486(38.97%)               497(39.86%)    486(38.97%)    
  III                     41198(12.45%)    293(23.5%)                281(22.53%)    293(23.5%)     
  ER                                                      \< 0.001                                 0.899
  Negative                74369(22.48%)    141(11.31%)               139(11.15%)    141(11.31%)    
  Positive                256417(77.52%)   1106(88.69%)              1108(88.85%)   1106(88.69%)   
  PR                                                      \< 0.001                                 0.844
  Negative                107456(32.49%)   265(21.25%)               261(20.93%)    265(21.25%)    
  Positive                223330(67.51%)   982(78.75%)               986(79.07%)    982(78.75%)    
  HR                                                      \< 0.001                                 0.898
  Negative                69892(21.13%)    135(10.83%)               137(10.99%)    135(10.83%)    
  Positive                260894(78.87%)   1112(89.17%)              1110(89.01%)   1112(89.17%)   
  nLN                                                     \< 0.001                                 0.773
  0                       12438(3.76%)     37(2.97%)                 38(3.05%)      37(2.97%)      
  1-10                    220826(66.76%)   772(61.91%)               788(63.19%)    772(61.91%)    
  \>10                    97522(29.48%)    438(35.12%)               421(33.76%)    438(35.12%)    
  Surgery                                                 \< 0.001                                 1.000
  BCS                     202389(61.18%)   699(56.05%)               699(56.05%)    699(56.05%)    
  Mastectomy              128397(38.82%)   548(43.95%)               548(43.95%)    548(43.95%)    
  Radiotherapy                                            0.029                                    0.326
  Without                 144356(43.64%)   506(40.58%)               482(38.65%)    506(40.58%)    
  With                    186430(56.36%)   741(59.42%)               765(61.35%)    741(59.42%)    
  Chemotherapy                                            \< 0.001                                 0.658
  Without                 168950(51.08%)   552(44.27%)               563(45.15%)    552(44.27%)    
  With                    161836(48.92%)   695(55.73%)               684(54.85%)    695(55.73%)    

\**P* values obtained from the Chi squared test.

\*Stage TNM, T, N-classification according to the 8^th^ edition of AJCC staging.

Abbreviations: IDC: Infiltrating duct carcinoma.

PSM: propensity score matching.

IMPC: Invasive micropapillary carcinoma.

ER: Estrogen receptor.

PR: Progesterone receptor.

HR: Hormone receptor.

BCS: Breast conserving surgery.

nLN: number of lymph node resected.

###### 

Comparisons of patient characteristics of the study population in the train and validation cohorts

                          Train cohort     Validation cohort                                            
  ----------------------- ---------------- ------------------- ---------- --------------- ------------- ----------
  Age                                                          0.002                                    0.006
  Young                   140885(57.38%)   497(52.75%)                    47233(57.1%)    141(49.13%)   
  Old                     107179(42.62%)   463(47.25%)                    35489(42.9%)    146(50.87%)   
  Race                                                         0.012                                    0.672
  White                   197182(79.92%)   726(76.44%)                    65658(79.37%)   225(78.4%)    
  Black                   27090(10.79%)    126(13.6%)                     9069(10.96%)    36(12.54%)    
  Other                   23792(9.29%)     108(9.96%)                     7995(9.66%)     26(9.06%)     
  Marital status                                               0.109                                    0.669
  Married                 154151(62.4%)    574(60.73%)                    51544(62.31%)   172(59.93%)   
  Single                  37505(14.75%)    168(17.23%)                    12546(15.17%)   48(16.72%)    
  Divorce                 56408(22.84%)    218(22.04%)                    18632(22.52%)   67(23.34%)    
  Laterality                                                   0.537                                    0.046
  Left                    125472(50.66%)   502(52.17%)                    42073(50.86%)   125(43.55%)   
  Right                   122558(49.32%)   458(47.83%)                    40638(49.13%)   162(56.45%)   
  Unknown                 34(0.01%)        0(0%)                          11(0.01%)       0(0%)         
  Location                                                     0.001                                    0.531
  Central portion         11432(4.96%)     47(5.51%)                      3758(4.54%)     17(5.92%)     
  Upper-inner quadrant    30673(12.16%)    142(13.25%)                    10407(12.58%)   34(11.85%)    
  Lower-inner quadrant    14653(5.94%)     65(6.33%)                      4941(5.97%)     19(6.62%)     
  Upper-outer quadrant    89634(35.94%)    282(29.66%)                    29588(35.77%)   90(31.36%)    
  Lower-outer quadrant    18343(7.32%)     79(8.56%)                      6269(7.58%)     26(9.06%)     
  Other                   83329(33.68%)    345(36.69%)                    27759(33.56%)   101(35.19%)   
  Differentiation grade                                        0.023                                    0.892
  Moderate-well           99655(40.74%)    351(39.27%)                    33184(40.12%)   114(39.72%)   
  Undifferentiated-Poor   148409(59.26%)   609(60.73%)                    49538(59.88%)   173(60.28%)   
  T-classification\*                                           \< 0.001                                 0.005
  T1                      155485(62.92%)   545(57.44%)                    52096(62.98%)   167(58.19%)   
  T2                      75235(30.22%)    299(30.95%)                    24893(30.09%)   89(31.01%)    
  T3                      11318(4.39%)     84(8.56%)                      3701(4.47%)     25(8.71%)     
  T4                      6026(2.47%)      32(3.05%)                      2032(2.46%)     6(2.09%)      
  N-classification \*                                          \< 0.001                                 \<0.001
  N0                      164426(65.77%)   463(46.19%)                    54770(66.21%)   142(49.48%)   
  N1                      60639(24.53%)    308(32.47%)                    20285(24.52%)   91(31.71%)    
  N2                      15120(6.41%)     103(10.79%)                    5078(6.14%)     31(10.8%)     
  N3                      7879(3.29%)      86(10.55%)                     2589(3.13%)     23(8.01%)     
  Stage \*                                                     \< 0.001                                 \< 0.001
  I                       123214(49.36%)   356(35.87%)                    41072(49.65%)   112(39.02%)   
  II                      93990(37.87%)    374(39.86%)                    31312(37.85%)   112(39.02%)   
  III                     30860(12.77%)    230(24.27%)                    10338(12.5%)    63(21.95%)    
  ER                                                           \< 0.001                                 \< 0.001
  Negative                55901(23.04%)    111(12.19%)                    18468(22.33%)   30(10.45%)    
  Positive                192163(76.96%)   849(87.81%)                    64254(77.67%)   257(89.55%)   
  PR                                                           \< 0.001                                 0.001
  Negative                80765(33.19%)    198(24.03%)                    26691(32.27%)   67(23.34%)    
  Positive                167299(66.81%)   762(75.97%)                    56031(67.73%)   220(76.66%)   
  HR                                                           \<0.001                                  \<0.001
  Negative                52510(21.66%)    105(11.61%)                    17382(21.01%)   30(10.45%)    
  Positive                195554(78.34%)   855(88.39%)                    65340(78.99%)   257(89.55%)   
  nLN                                                          0.001                                    0.053
  0                       9356(3.76%)      31(2.97%)                      3082(3.73%)     6(2.09%)      
  1-10                    165603(66.76%)   592(61.91%)                    55223(66.76%)   180(62.72%)   
  \>10                    73105(29.48%)    337(35.12%)                    24417(29.52%)   101(35.19%)   
  Surgery                                                      \<0.001                                  0.539
  BCS                     151925(60.66%)   529(54.4%)                     50464(61%)      170(59.23%)   
  Mastectomy              96139(39.34%)    431(45.6%)                     32258(39%)      117(40.77%)   
  Radiotherapy                                                 0.303                                    0.008
  Without                 108231(44.04%)   403(41.38%)                    36125(43.67%)   103(35.89%)   
  With                    139833(55.96%)   557(58.62%)                    46597(56.33%)   184(64.11%)   
  Chemotherapy                                                 \< 0.001                                 0.065
  Without                 126677(50.84%)   421(41.74%)                    42273(51.1%)    131(45.64%)   
  With                    121387(49.16%)   539(58.26%)                    40449(48.9%)    156(54.36%)   

\**P* values obtained from the Chi squared test.

\*Stage TNM, T, N-classification according to the 8^th^ edition of AJCC staging.

Abbreviations: IDC: Infiltrating duct carcinoma.

PSM: propensity score matching.

IMPC: Invasive micropapillary carcinoma.

ER: Estrogen receptor.

PR: Progesterone receptor.

HR: Hormone receptor.

BCS: Breast conserving surgery.

nLN: number of lymph node resected.

###### 

Breast cancer-specific death in univariate and multivariate analysis based on competing risk model.

  Risk Factors            Univariate analysis^\#^   Multivariate analysis^\#^                      
  ----------------------- ------------------------- --------------------------- ------------------ ----------
  Age                                                                                              
  Young                   Ref                                                                      
  Old                     0.8(0.57-1.12)            0.196                                          
  Race                                                                                             
  White                   Ref                                                   Ref                
  Black                   1.99(1.31-3)              0.001                       2.06(1.39-3.04)    \< 0.001
  Other                   0.58(0.3-1.15)            0.119                       0.59(0.28-1.24)    0.166
  Marital status                                                                                   
  Married                 Ref                                                                      
  Single                  1.31(0.83-2.06)           0.249                                          
  Divorce                 1.46(1.00-2.15)           0.053                                          
  Laterality                                                                                       
  Left                    Ref                                                                      
  Right                   1.07(0.77-1.5)            0.685                                          
  Location                                                                                         
  Central portion         Ref                                                                      
  Upper-inner quadrant    0.49(0.18-1.32)           0.158                                          
  Lower-inner quadrant    0.74(0.25-2.21)           0.591                                          
  Upper-outer quadrant    0.92(0.39-2.16)           0.847                                          
  Lower-outer quadrant    0.73(0.27-2.00)           0.539                                          
  Other                   1.20(0.52-2.77)           0.668                                          
  Histology                                                                                        
  IDC                     Ref                                                   Ref                
  IMPC                    0.63(0.44-0.9)            0.012                       0.56(0.39-0.81)    0.002
  Differentiation grade                                                                            
  Moderate-well           Ref                                                   Ref                
  Undifferentiated-Poor   3.25(2.29-4.61)           \< 0.001                    2.3(1.54-3.42)     \< 0.001
  T-classification\*                                                                               
  T1                      Ref                                                   Ref                
  T2                      2.33(1.52-3.57)           \< 0.001                    1.57(1.00-2.47)    0.049
  T3                      6.21(3.84-10.04)          \< 0.001                    2.93(1.62-5.32)    \< 0.001
  T4                      15.35(9.2-25.61)          \< 0.001                    5.41(2.91-10.06)   \< 0.001
  N-classification \*                                                                              
  N0                      Ref                                                   Ref                
  N1                      2.88(1.78-4.67)           \< 0.001                    2.97(1.69-5.21)    \< 0.001
  N2                      4.36(2.49-7.61)           \< 0.001                    3.54(1.73-7.26)    0.001
  N3                      9.98(6.03-16.53)          \< 0.001                    6.38(3.01-13.5)    \< 0.001
  Stage \*                                                                                         
  I                       Ref                                                                      
  II                      2.94(1.61-5.37)           \< 0.001                                       
  III                     10.23(5.78-18.09)         \< 0.001                                       
  ER                                                                                               
  Negative                Ref                                                                      
  Positive                0.29(0.2-0.43)            \< 0.001                                       
  PR                                                                                               
  Negative                Ref                                                                      
  Positive                0.34(0.24-0.48)           \< 0.001                                       
  HR                                                                                               
  Negative                Ref                                                   Ref                
  Positive                0.31(0.21-0.46)           \< 0.001                    0.44(0.29-0.68)    \< 0.001
  nLN                                                                                              
  0                       Ref                                                   Ref                
  1-10                    0.31(0.15-0.64)           0.002                       0.27(0.13-0.56)    \< 0.001
  \>10                    0.67(0.33-1.39)           0.284                       0.17(0.08-0.39)    \< 0.001
  Surgery                                                                                          
  BCS                     Ref                                                   Ref                
  Mastectomy              2.81(1.96-4.02)           \< 0.001                    1.46(0.95-2.25)    0.087
  Radiotherapy                                                                                     
  Without                 Ref                                                                      
  With                    0.82(0.58-1.14)           0.232                                          
  Chemotherapy                                                                                     
  Without                 Ref                                                   Ref                
  With                    2.24(1.53-3.28)           \< 0.001                    0.77(0.49-1.2)     0.250

\#Univariate and multivariate analyses were conducted using competing risk model.

\*Stage TNM, T, N-classification according to the 8th edition of AJCC staging.

SHR: Subdistribution hazard ratio.

HR: Hormone receptor.

ER: Estrogen receptor.

PR: Progesterone receptor.

IDC: Infiltrating duct carcinoma.

IMPC: Invasive micropapillary carcinoma.

BCS: Breast conserving surgery.

nLN: Number of lymph node resected.

###### 

Point assignment and prognostic score in the nomogram

  Variable                 Risk score
  ------------------------ ---------------------------------
  Race                     
  White                    31
  Black                    70
  Other                    0
  Histology                
  IDC                      31
  IMPC                     0
  Differentiation grade    
  Undifferentiated-Poor    46
  Moderate-well            0
  T-classification\*       
  T1                       0
  T2                       27
  T3                       62
  T4                       97
  N-classification\*       
  N0                       0
  N1                       59
  N2                       69
  N3                       100
  HR                       
  Negative                 45
  Positive                 0
  nLN                      
  0                        84
  1-10                     22
  \>10                     0
  Total prognostic score   Estimated 10-year BCSD rate (%)
  116                      0.05
  156                      0.10
  197                      0.20
  242                      0.40
  259                      0.50
  274                      0.60
  289                      0.70
  305                      0.80
  325                      0.90

\*Stage TNM, T, N-classification according to the 8^th^ edition of AJCC staging.

IDC: Infiltrating duct carcinoma.

IMPC: Invasive micropapillary carcinoma.

ER: Estrogen receptor.

PR: Progesterone receptor.

nLN: Number of lymph node resected.
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